175 related articles for article (PubMed ID: 32905192)
1. Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis.
Mantravadi S; George M; Brensinger C; Du M; Baker JF; Ogdie A
BMC Rheumatol; 2020; 4():39. PubMed ID: 32905192
[TBL] [Abstract][Full Text] [Related]
2. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
George MD; Baker JF; Ogdie A
J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
[TBL] [Abstract][Full Text] [Related]
3. Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis.
Ogdie A; Maksabedian Hernandez EJ; Shaw Y; Stolshek B; Michaud K
ACR Open Rheumatol; 2022 Nov; 4(11):935-941. PubMed ID: 35971643
[TBL] [Abstract][Full Text] [Related]
4. No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients.
Wu JJ; Rowan CG; Bebchuk JD; Anthony MS
J Drugs Dermatol; 2015 Feb; 14(2):159-66. PubMed ID: 25689811
[TBL] [Abstract][Full Text] [Related]
5. Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis.
Katz G; Ogdie A; Baker JF; George MD
Clin Rheumatol; 2022 May; 41(5):1323-1331. PubMed ID: 35084601
[TBL] [Abstract][Full Text] [Related]
6. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study.
Otsuka Y; Kiyohara C; Kashiwado Y; Sawabe T; Nagano S; Kimoto Y; Ayano M; Mitoma H; Akahoshi M; Arinobu Y; Niiro H; Akashi K; Horiuchi T
PLoS One; 2018; 13(4):e0196368. PubMed ID: 29694426
[TBL] [Abstract][Full Text] [Related]
7. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
8. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
9. Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study.
Kang EH; Jin Y; Tong AY; Desai RJ; Kim SC
Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1383-1391. PubMed ID: 31376333
[TBL] [Abstract][Full Text] [Related]
10. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
[TBL] [Abstract][Full Text] [Related]
11. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
[TBL] [Abstract][Full Text] [Related]
13. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
van Mens LJJ; de Jong HM; Fluri I; Nurmohamed MT; van de Sande MGH; Kok M; van Kuijk AWR; Baeten D
Ann Rheum Dis; 2019 May; 78(5):610-616. PubMed ID: 30808625
[TBL] [Abstract][Full Text] [Related]
14. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.
Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM
Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218
[TBL] [Abstract][Full Text] [Related]
15. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
16. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.
Manders SH; Kievit W; Jansen TL; Stolk JN; Visser H; Schilder AM; Vonkeman HE; Adang E; van de Laar MA; van Riel PL
J Rheumatol; 2016 Oct; 43(10):1787-1794. PubMed ID: 27481900
[TBL] [Abstract][Full Text] [Related]
19. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
20. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]